Evaluation of PDE5 and PDE9 Expression in Benign and Malignant Breast Tumors

Archives of Medical Research

Volumn 43, Issue 6, 2012, Pages 470-475

  Karami Tehrani, Fatemeh ^a   Moeinifard, Marzieh ^a   Aghaei, Mahmoud ^a,b   Atri, Morteza ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Benign breast disease; Breast cancer; PDE5 and PDE9 expression

Indexed keywords

PHOSPHODIESTERASE; PHOSPHODIESTERASE IX; PHOSPHODIESTERASE V; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ADULT; AGED; BREAST NEOPLASMS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; HUMANS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84867848083     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.08.006     Document Type: Article

References (27)

1. Berry D.A., Cronin K.A., Plevritis S.K., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353:1784-1792.
2. American Cancer Society. 1-800-ACS-2345, http://www.cancer.org.
3. Cheang M., van de Rijn M., Nielsen T.O. Gene expression profiling of breast cancer. Annu Rev Pathol 2008, 3:67-97.
4. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995, 75:725-748.
5. Perry M.J., Higgs G.A. Chemotherapeutic potential of phosphodiesterase inhibitors. Curr Opin Chem Biol 1998, 2:472-481.
6. Lincoln T.M., Cornwell T.L. Intracellular cyclic GMP receptor proteins. FASEB J 1993, 7:328-380.
7. Fisher D.A., Smith J.F., Pillar J.S., et al. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 1998, 19:15559-15564.
8. Wharton J., Strange J.W., Moller G.M., et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005, 172:105-113.
9. Thompson W.J., Piazza G.A., Li H., et al. Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res 2000, 60:3338-3342.
10. Horvath A., Korde L., Greene M.H., et al. Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors. Cancer Res 2009, 69:5301-5306.
11. Hait W.N., Weiss B. Increased cyclic nucleotide phosphodiesterase activity in leukaemic lymphocytes. Nature (London) 1976, 259:321-323.
12. Piazza G.A., Sperl G., Whitehead C.M., et al. Cyclic GMP phosphodiesterase (cG PDE) overexpression in human pancreatic carcinomas and a target for selective apoptotic antineoplastic drugs. Gastroenterology 2001, 120(suppl 1):A75.
13. Piazza G.A., Klein-Szanto A.J., Ahnen D.J., et al. Overexpression of cGMP phosphodiesterase (cG PDE) in colonic neoplasias compared to normal mucosa. Gastroenterology 2000, 118(suppl 2):A282.
14. Piazza G.A., Klein-Szanto A.J., Xu A., et al. Phosphodiesterase 5 overexpression in human non-small cell lung tumors compared to normal bronchial epithelium. Proc Am Assoc Cancer Res 2001, 42:811.
15. McDaniel N.L., Chen X.L., Singer H.A., et al. Nitrovasodilators relax arterial smooth muscle by decreasing [Ca2+]i, uncoupling stress from myosin phosphorylation. Am J Physiol 1992, 263:C461-C467.
16. Zhu B., Vemavarapu L., Thompson W.J., et al. Suppression of cyclic GMP specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 2005, 94:336-350.
17. Zhu B., Strada S.J. The novel function of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr Top Med Chem 2007, 7:437-454.
18. Whitehead C.M., Earle K.A., Fetter J., et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2003, 2:479-488.
19. Sarfati M., Mateo V., Baudet S., et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 2003, 101:265-269.
20. Hirsh L., Dantes A., Suh B., et al. Phosphodiesterase inhibitors as anti-cancer drugs. Biochem Pharmacol 2004, 68:981-988.
21. Aghaei M., Karami-Tehrani F., Salami S., et al. Adenosine deaminase activity in the serum and malignant tumors of breast cancer: the assessment of isoenzyme ADA1 and ADA2 activities. Clin Biochem 2005, 38:887-891.
22. Aghaei M., Karami-Tehrani F., Salami S., et al. Diagnostic value of adenosine deaminase activity in benign and malignant breast tumors. Arch Med Res 2009, 41:14-18.
23. Aghaei M., Panjehpour M., Karami-Tehrani F., et al. Molecular mechanism of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway. J Cancer Res Clin Oncol 2011, 137:1511-1523.
24. Aghaei M., Karami-Tehrani F., Panjehpour M., et al. Adenosine induces cell-cycle arrest and apoptosis in androgen-dependent and -independent prostate cancer cell lines, LNcap-FGC-10, DU-145, and PC3. Prostate 2012, 72:361-375.
25. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
26. Fallahian F., Karami-Tehrani F., Salami S., et al. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and negative breast cancer cell lines. FEBS J 2011, 3360-3369.
27. Saravani S., Karami-Tehrani F., Hashemi M., et al. Inhibition of phosphodiesterase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468. Cell Prolif 2012, 45:199-206.